Shots:
There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United StatesÂ
Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity Â
Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
